Arrowhead
Sarepta Licenses Clinical, Preclinical siRNA Candidates From Arrowhead, Enters Discovery Deal
Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.
Arrowhead Pharmaceuticals Doses First Renal Cell Carcinoma Patient With RNA Interference Agent
The Phase Ib trial will include exploratory analyses of patients' serum biomarkers and the correlation between HIF2a gene expression and response to ARO-HIF2.